Literature DB >> 32267316

Are DOACs a Good Bang for Your Buck in Atrial Fibrillation Prevention in Real-Life?

Márcio Bittencourt1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32267316      PMCID： PMC7792714          DOI： 10.36660/abc.20200120

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN： 0066-782X            Impact factor:   2.000


× No keyword cloud information.
  9 in total

1.  Stability of International Normalized Ratios in Patients Taking Long-term Warfarin Therapy.

Authors:  Sean D Pokorney; DaJuanicia N Simon; Laine Thomas; Bernard J Gersh; Elaine M Hylek; Jonathan P Piccini; Eric D Peterson
Journal:  JAMA       Date:  2016-08-09       Impact factor: 56.272

2.  Apixaban versus warfarin in patients with atrial fibrillation.

Authors:  Christopher B Granger; John H Alexander; John J V McMurray; Renato D Lopes; Elaine M Hylek; Michael Hanna; Hussein R Al-Khalidi; Jack Ansell; Dan Atar; Alvaro Avezum; M Cecilia Bahit; Rafael Diaz; J Donald Easton; Justin A Ezekowitz; Greg Flaker; David Garcia; Margarida Geraldes; Bernard J Gersh; Sergey Golitsyn; Shinya Goto; Antonio G Hermosillo; Stefan H Hohnloser; John Horowitz; Puneet Mohan; Petr Jansky; Basil S Lewis; Jose Luis Lopez-Sendon; Prem Pais; Alexander Parkhomenko; Freek W A Verheugt; Jun Zhu; Lars Wallentin
Journal:  N Engl J Med       Date:  2011-08-27       Impact factor: 91.245

3.  Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry.

Authors:  Sean D Pokorney; DaJuanicia N Simon; Laine Thomas; Gregg C Fonarow; Peter R Kowey; Paul Chang; Daniel E Singer; Jack Ansell; Rosalia G Blanco; Bernard Gersh; Kenneth W Mahaffey; Elaine M Hylek; Alan S Go; Jonathan P Piccini; Eric D Peterson
Journal:  Am Heart J       Date:  2015-04-01       Impact factor: 4.749

4.  Comparison of real-world outcomes in patients with nonvalvular atrial fibrillation treated with direct oral anticoagulant agents or warfarin.

Authors:  Manasi Datar; Concetta Crivera; Heather Rozjabek; Ibrahim M Abbass; Yihua Xu; Margaret K Pasquale; Jeff R Schein; George A Andrews
Journal:  Am J Health Syst Pharm       Date:  2019-02-09       Impact factor: 2.637

Review 5.  Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.

Authors:  José A López-López; Jonathan A C Sterne; Howard H Z Thom; Julian P T Higgins; Aroon D Hingorani; George N Okoli; Philippa A Davies; Pritesh N Bodalia; Peter A Bryden; Nicky J Welton; William Hollingworth; Deborah M Caldwell; Jelena Savović; Sofia Dias; Chris Salisbury; Diane Eaton; Annya Stephens-Boal; Reecha Sofat
Journal:  BMJ       Date:  2017-11-28

6.  Modeling patients' time, travel, and monitoring costs in anticoagulation management: societal savings achievable with the shift from warfarin to direct oral anticoagulants.

Authors:  Aapeli Leminen; Mikko Pyykönen; Juho Tynkkynen; Markku Tykkyläinen; Tiina Laatikainen
Journal:  BMC Health Serv Res       Date:  2019-11-27       Impact factor: 2.655

7.  Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.

Authors:  Daniel E Singer; Anne S Hellkamp; Jonathan P Piccini; Kenneth W Mahaffey; Yuliya Lokhnygina; Guohua Pan; Jonathan L Halperin; Richard C Becker; Günter Breithardt; Graeme J Hankey; Werner Hacke; Christopher C Nessel; Manesh R Patel; Robert M Califf; Keith A A Fox
Journal:  J Am Heart Assoc       Date:  2013-02-19       Impact factor: 5.501

8.  Burden of disease from atrial fibrillation in adults from seven countries in Latin America.

Authors:  Luz Cubillos; Alexandra Haddad; Andreas Kuznik; Joaquin Mould-Quevedo
Journal:  Int J Gen Med       Date:  2014-09-02

9.  Anticoagulation Therapy in Patients with Non-valvular Atrial Fibrillation in a Private Setting in Brazil: A Real-World Study.

Authors:  Pedro Gabriel Melo de Barros E Silva; Henry Sznejder; Rafael Vasconcellos; Georgette M Charles; Hugo Tannus F Mendonca-Filho; Jack Mardekian; Rodrigo Nascimento; Stephen Dukacz; Manuela Di Fusco
Journal:  Arq Bras Cardiol       Date:  2020-03       Impact factor: 2.000
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.